Nivolumab in NSCLC: latest evidence and clinical potential-Reference-Cited by-同舟云学术

Nivolumab in NSCLC: latest evidence and clinical potential

Published:2015-01-20 Issue:2 Volume:7 Page:85-96
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Sundar Raghav¹,Cho Byoung-Chul²,Brahmer Julie R.³,Soo Ross A.⁴

Affiliation:

1. Department of Haematology–Oncology, National University Cancer Institute, National University Health System, Singapore

2. Division of Medical Oncology, Yonsei Cancer Center, Seoul, South Korea

3. Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USA

4. Department of Haematology–Oncology, National University Cancer Institute, National University Health System, 1E Kent Ridge Road, NUHS Tower Block Level 7, Singapore 119228

Abstract

New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1758834014567470

Reference77 articles.

1. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions

2. Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Cited by 192 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IRE1α‐XBP1s axis regulates SREBP1‐dependent MRP1 expression to promote chemoresistance in non‐small cell lung cancer cells;Thoracic Cancer;2024-09-08

2. Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen;2024-07-08

3. Optimizing the Design and Geometry of T Cell–Engaging Bispecific Antibodies Targeting CEA in Colorectal Cancer;Molecular Cancer Therapeutics;2024-04-18

4. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges;Frontiers in Immunology;2024-04-09

5. Combined Metronomic Chemo-immunotherapy (CMCI) in Head and Neck Cancers–An Experience from a Developing Country;Indian Journal of Surgical Oncology;2024-02-20